Quality Matters - Hematopoietic Stem Cell Transplantation versus Transfusion and Chelation in Thalassemia Major

Area of Science:

• Hematology
• Pediatric Medicine
• Transplantation Science

Background:

• Thalassemia major is a severe inherited blood disorder requiring lifelong treatment.
• Current management involves regular blood transfusions and iron chelation therapy, impacting quality of life.
• Stem cell transplantation offers a potential curative approach.

Purpose of the Study:

• To compare the quality of life (QoL) in children with thalassemia major who have undergone allogeneic stem cell transplantation (SCT) versus those managed with regular transfusions.
• To assess the long-term impact of SCT on QoL in this patient population.

Main Methods:

• A cohort study comparing 40 children post-SCT with 40 children and 20 adults on regular transfusion and iron chelation.
• Quality of life was evaluated using the Pediatric Quality of Life Inventory 4.0 Generic Core Scale.
• Statistical analysis was performed to compare QoL scores between groups.

Main Results:

• Children undergoing SCT demonstrated significantly higher mean total, psychosocial, and physical QoL scores (92, 91, 92.8) compared to children on transfusion (83, 82.7, 83.6).
• Adults on transfusion therapy reported substantially lower QoL scores (74.9, 76, 73.9).
• QoL scores in the transfusion group declined notably in the second decade of life (P<0.05).

Conclusions:

• Allogeneic stem cell transplantation is associated with improved quality of life in children with thalassemia major.
• SCT represents a superior treatment modality for enhancing long-term well-being in thalassemia major patients.
• Regular transfusion therapy negatively impacts QoL, particularly in adolescents and adults.